Judge Won't Toss $950M COVID-19 Vax Trade Secrets Row

By Andrew Karpan (August 1, 2022, 5:23 PM EDT) -- A Seattle federal judge has ruled that it's too soon to decide whether an Indian generic-drug maker can use its minimal connections to the U.S. to ditch a $950 million suit over allegedly stolen trade secrets from a small American company with a proprietary mRNA platform to develop a new COVID-19 vaccine in India.

The nearly billion-dollar legal saga between a Seattle business called HDT Bio Corp. and Emcure Pharmaceuticals — based in Pune, India — will continue in Washington federal court for now, U.S. District Judge James L. Robart ruled on Friday.

"The present record provides an insufficient basis for the court to determine whether it has personal jurisdiction...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!